TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06682169: A Randomized, Open Label, Positive Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of the Selected Regimen of Rovadicitinib in Moderate to Severe Chronic Graft-versus-host Disease in T

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 182 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,855,832

Rescue Site Savings

+$3,205,792

Unlock Full NCT06682169 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06682169 Rescue Dossier →